I hope you're right about the trials. I suspect there is more to the story and obviously we're not getting all of it yet. Getting the IP out of BGEN without compensating the company isn't that easy because the patent applications have been assigned to BGEN for a year or two (they became public as attachments to the BCA with SAGA) and their recent revised agreement taking BGEN out of the BCA assigned BGEN with a $160 million FMV. I do understand there are ways it can happen, but they will likely come with some legal risks due to many public disclosures that the IP belongs to ENZC, then later, more specifically, to BGEN, which was and is a subsidiary of ENZC, and the fact that ENZC paid the tabs for the research and their salaries while working on the IP. So, it's hard to image the CCC's can just walk away from a public company with its assets. I'm guessing they need to manage that risk by keeping us happy. JMHO.